Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 31;17(11):12812-20.
doi: 10.3390/molecules171112812.

Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains

Affiliations

Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains

Martin Krátký et al. Molecules. .

Abstract

The increasing emergence especially of drug-resistant tuberculosis has led to a strong demand for new anti-tuberculosis drugs. Eighteen salicylanilide benzoates were evaluated for their inhibition potential against Mycobacterium tuberculosis, Mycobacterium avium and two strains of Mycobacterium kansasii; minimum inhibitory concentration values ranged from 0.5 to 16 μmol/L. The most active esters underwent additional biological assays. Four benzoates inhibited effectively the growth of five multidrug-resistant strains and one extensively drug-resistant strain of M. tuberculosis at low concentrations (0.25–2 μmol/L) regardless of the resistance patterns. The highest rate of multidrug-resistant mycobacteria inhibition expressed 4-chloro-2-[4-(trifluoromethyl)-phenylcarbamoyl]phenyl benzoate (0.25–1 μmol/L). Unfortunately, the most potent esters were still considerably cytotoxic, although mostly less than their parent salicylanilides.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
Synthesis of salicylanilides S and corresponding benzoates 1 (R1 for esters 1 = 4-Cl, 5-Cl, 4-Br; R2 = 3-Cl, 4-Cl, 3,4-diCl, 3-Br, 4-Br, 3-F, 4-F, 3-CF3, 4-CF3).

References

    1. Krátký M., Vinšová J. Advances in the Development of Antituberculotics Acting on Multidrug-Resistant Strains. Chem. Listy. 2010;104:998–1005.
    1. Sturdy A., Goodman A., Jose R.J., Loyse A., O’Donoghue M., Kon O.M., Dedicoat M.J., Harrison T.S., John L., Lipman M., et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: A study of injectable use and toxicity in practice. J. Antimicrob. Chemother. 2011;66:1815–1820. - PubMed
    1. La Rosa V., Poce G., Canseco J.O., Buroni S., Pasca M.R., Biava M., Raju R.M., Porretta G.C., Alfonso S., Battilocchio C., et al. MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. Antimicrob. Agents Chemother. 2012;56:324–331. - PMC - PubMed
    1. Grzegorzewicz A.E., Pham H., Gundi V.A.K.B., Scherman M.S., North E.J., Hess T., Jones V., Gruppo V., Born S.E.M., Kordulakova J., et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 2012;8:334–341. doi: 10.1038/nchembio.794. - DOI - PMC - PubMed
    1. Batt S.M., Jabeen T., Bhowruth V., Quill L., Lund P.A., Eggeling L., Alderwick L.J., Futterer K., Besra G.S. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl. Acad. Sci. USA. 2012;109:11354–11359. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources